Department of Neurosciences, Biomedicine and Movement Sciences, Neurology Section, University of Verona, Italy.
Int J Neuropsychopharmacol. 2022 Nov 17;25(11):933-935. doi: 10.1093/ijnp/pyac042.
Chemosensory (i.e., olfaction and taste) dysfunction is common in neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease, and dementia), psychiatric (e.g., depression, bipolar disorders, other conditions), and postinfectious (i.e., long COVID) diseases and in the elderly. Despite its impact on patients' quality of life, no established treatment for taste disorders exists so far. A recent report on the effect of pramipexole, a D2/D3 agonist, on taste performance in healthy participants provides support for a new potential therapeutic target for taste dysfunction to be tested in future randomized, placebo-controlled, clinical trials across several populations reporting gustatory symptoms.
化感（即嗅觉和味觉）功能障碍在神经退行性疾病（如帕金森病、阿尔茨海默病和痴呆症）、精神疾病（如抑郁症、双相情感障碍、其他疾病）和感染后疾病（如长期 COVID）以及老年人中很常见。尽管它对患者的生活质量有影响，但迄今为止，还没有针对味觉障碍的既定治疗方法。最近有一份关于普拉克索（一种 D2/D3 激动剂）对健康参与者味觉表现影响的报告，为味觉功能障碍的一个新的潜在治疗靶点提供了支持，该靶点将在未来针对有味觉症状的多个人群的随机、安慰剂对照临床试验中进行测试。
